What question did this study set out to answer?

This study aims to assess the differences in post-stroke antidiabetic treatment patterns between newly diagnosed T2D and established T2D individuals.

June 7, 2026

2350-P: Unmet Need in Post-Stroke Antidiabetic Treatment Patterns among Individuals Newly Diagnosed with Type 2 Diabetes (T2D) during Ischemic Stroke Hospitalization

Key Points

This study aims to assess the differences in post-stroke antidiabetic treatment patterns between newly diagnosed T2D and established T2D individuals.
Retrospective, observational cohort study conducted on hospitalized individuals with ischemic stroke and T2D.
Data was sourced from the Premier Healthcare Database linked to a closed claims database from July 2017 to March 2023.
Descriptive analysis compared medication use, follow-up care, and clinical outcomes between newT2D and estT2D groups.
56% of 18,799 individuals received any antidiabetic medication; newT2D had lower rates (31%) compared to estT2D (66%).
Among those on medication, insulin usage was 19% in newT2D versus 45% in estT2D.
Newly diagnosed individuals had lower all-cause (17% vs 26%) and stroke-related (4% vs 5%) 180-day readmission rates.

Abstract

Introduction and Objective: Individuals with newly diagnosed T2D at the time of an ischemic stroke have worse outcomes, yet few studies have examined post-stroke antidiabetic treatment patterns among those with newly diagnosed T2D during stroke hospitalization versus those with previously established T2D. This study examined the differences between the two groups. Methods: This retrospective, observational cohort study identified adults hospitalized with ischemic stroke and evidence of T2D prior to or during the hospitalization from 07/01/2017 to 03/31/2023 in the Premier Healthcare Database linked to a closed claims database. Descriptive analysis compared post-stroke antidiabetic medication (ADM) use, follow-up care, and clinical outcomes between individuals with a T2D diagnosis or ADM use before hospitalization (estT2D) and those with a discharge T2D diagnosis or laboratory values (glycated hemoglobin ≥ 6.5%) indicating T2D during hospitalization without prior evidence of T2D (newT2D). Results: During 180-day post discharge follow-up, among 18,799 individuals with T2D (21% newT2D, 71% estT2D), 56% received any ADM; individuals with newT2D were less likely to receive any ADM than those with estT2D (31% vs 66%). Among those who received any ADM, 38% received insulin (19% newT2D, 45% estT2D), followed by biguanide, sulfonylurea, DPP4i, SGLT2i, and GLP1RA. Individuals with newT2D were less likely to have follow-up with any health care professional (57% vs 65%), and were mostly seen by a primary care provider (49% vs 59%). However, individuals with newT2D had lower all-cause 180-day readmission (17% vs 26%), and lower stroke-related 180-day readmission (4% vs 5%) compared to those with estT2D. Conclusion: Individuals with newly diagnosed T2D received less post-discharge ADM and follow-up care while experienced fewer 180-day readmissions after stroke hospitalization compared to those with established T2D, highlighting potential unmet needs in diabetes management after stroke. Disclosure C. Zhong: None. L. Xie: None. J. Noone: Employee; Current; Novo Nordisk. C. Muhammad: Employee; Current; Novo Nordisk. Stock/Shareholder; Current; Novo Nordisk. S. Ikpe: None. Z. Cao: Other - I am an employee of Premier Inc, which receives payment from Novo Nordisk to conduct the research; Current; Novo Nordisk. S. Krishnaswami: Research Support; Current; Novo Nordisk. Employee; Current; Premier Inc. A. de Havenon: Consultant; Current; Novo Nordisk, UpToDate.

Mark Helpful

Bookmark

Relay